الفهرس 
FDG avidity at PET/CT in patients with metastatic breast cancer and response assessment in relation to molecular subtypes
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Approximately 5% to 10% of breast cancers are metastatic at diagnosis; of these, approximately one-fifth will survive 5 years. FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes. Material and methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and basal like subtype (8 patients).All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end of therapy. The remaining 6 patient didn{u2019}t perform proved follow up PET-CT being negative for metastatic lesions. Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions, 49 metastatic lesions in LNs, 24 metastatic lesions in lung, 8 metastatic lesions in liver; while 39 metastatic bone lesions were detected by bone scan. Metastatic lesions in PET/CT were 76 lesions (46 lesions in LNs, 22 metastatic lung lesions and 8 metastatic lesions in liver)